Abstract: Objective To investigate the efficacy of entecavir combined with carvedilol in the treatment of hepatitis B virus (HBV) related cirrhosis complicated with esophagogastric varices (EGV). Methods Patients with HBV related cirrhosis complicated with EGV admitted to our hospital from April 2018 to May 2020 were selected. After enrollment, 35 patients continued entecavir antiviral therapy and were given carvedilol 10 mg orally daily.. Liver function, blood routine test, liver stiffness (LS) and gastroscope were examined at baseline, 48 weeks and 104 weeks respectively. Results The levels of alanine aminotransferase (ALT) were 33.71±11.18 IU/mL at baseline, 27.93±8.71 IU/mL at 48 weeks, and 25.57±7.18 IU/mL at 104 weeks, the differences were statistically significant (P<0.05). Similarly, aspartate aminotransferase (AST), alkaline phosphatase (ALP), glutamine transferase (GGT), baseline were significantly different from 48 weeks or 104 weeks (P<0.05). The level of platelet at baseline was not significantly different from 48 week and were significantly different from 104 week (P<0.05). The LS of patients at baseline, 48 weeks and 104 weeks were 18.24±8.73 kPa, 13.95±5.69 kPa and 12.12±4.20 kPa, respectively. There were significant differences between baseline and 48 weeks, baseline and 104 weeks (P<0.05). The degree of EGV was significantly improved at 48 weeks and 104 weeks compared to baseline (P<0.05). Conclusion Long-term antiviral therapy with entecavir combined with carvedilol significantly improved the degree of liver cirrhosis and prevented esophageal and gastric varices bleeding.

Key words: Hepatitis B cirrhosis, Esophagogastric Varices, Entecavir, Carvedilol